

# Appendix 3Z

## Final Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity:</b> Fluence Corporation Limited (ASX:FLC)
<b>ACN:</b> 127 734 196

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	Eytan Levy
<b>Date of last notice</b>	20 July 2017
<b>Date that director ceased to be director</b>	31 August 2017

### Part 1 – Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>
None

+ See chapter 19 for defined terms.

**Appendix 3Z**  
**Final Director's Interest Notice**

---

**Part 2 – Director's relevant interests in securities of which the director is not the registered holder**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

<b>Name of holder &amp; nature of interest</b>	<b>Number &amp; class of securities</b>
<p>Note: Provide details of the circumstances giving rise to the relevant interest</p> <p>Beneficial owner of Ordinary Shares and Unlisted Options held in the name of ESOP Management and Trust Services Ltd.</p>	<p>(a) 9,267,810 Ordinary Shares</p> <p>(b) 5,000,000 Unlisted Options to acquire Ordinary Shares, consisting of:</p> <ul style="list-style-type: none"> <li>(i) 1,000,000 Unlisted Director Options, exercisable at \$0.30, expiring at 18/12/2018;</li> <li>(ii) 1,000,000 Unlisted Director Options, exercisable at \$0.40, expiring at 18/12/2019;</li> <li>(iii) 1,000,000 Unlisted Director Options, exercisable at \$0.40, expiring at 18/05/2020;</li> <li>(iv) 1,000,000 Unlisted Director Options, exercisable at \$0.40, expiring at 18/05/2021;</li> <li>(v) 500,000 Unlisted Options with exercise price of \$1.20, expiring at 13/7/2021 (4 years from issue), escrowed for 24 months; and</li> <li>(vi) 500,000 Unlisted Options with exercise price of \$1.50, expiring at 13/7/2021 (4 years from issue), escrowed for 24 months.</li> </ul>

**Part 3 – Director's interests in contracts**

<b>Detail of contract</b>	Share Exchange and Purchase Agreement, the terms of which were summarised in section 13.1(a) of the Company's Replacement Prospectus dated 23 October 2015.
<b>Nature of interest</b>	In accordance with the terms of the Share Exchange and Purchase Agreement, a right to receive Ordinary Shares as deferred consideration for the acquisition of Emefcy Limited, Israel.
<b>Name of registered holder (if issued securities)</b>	Not applicable

---

+ See chapter 19 for defined terms.

<b>No. and class of securities to which interest relates</b>	Up to a total of 3,104,551 Ordinary Shares following satisfaction of a prescribed milestone (summarised in section 13.6 of the Company's Replacement Prospectus dated 23 October 2015).
--------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

---

+ See chapter 19 for defined terms.